Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

Healthcare Cannabis
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

Bullboard (TSX:LABS)

View:
Prev ... 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 ... Next
Post by mdjbrownon Mar 19, 2024 11:51am

Havent seen much in the way of updates regarding

Medipharm's reported interests with New York City Ichan School of Medicine at Mount Sinai and Renowned Global Researcher Dr. Hurd on Opiod research. An update would be helpful as the opiod crisis ...more  
53
Discussion
Comment by subaru1ion Mar 19, 2024 11:26am

RE:RE:RE:LABS is also a "clinical stage" pharma company. "over 20

alleyesonme....I put the dogs chasing their own tails on ignore.   ya gotta.... https://www.youtube.com/watch?v=NrX_SBio8Tw
37
Discussion
Comment by alleyesonmeon Mar 19, 2024 11:21am

RE:RE:LABS is also a "clinical stage" pharma company. "over 20

This was stated by the CEO, if you don't want to take his word I'd suggest visiting various governmental health authorities websites, like the FDA, TGA, ANVISA, HEALTH CANADA, some ...more  
34
Discussion
Comment by QContinuum1on Mar 19, 2024 10:59am

RE:LABS is also a "clinical stage" pharma company. "over 20

Which trials are in late stage?  My 1.5e6 shares thank you in advance.
29
Discussion
Post by subaru1ion Mar 19, 2024 10:50am

Well everyone here have a great day today!!!! I've still

got about 1200 hulls to reload and want to get that done today...that's the plan at least.  I really love my MEC 9000 GN, it's a sweet machine, taking my sweet old time, I can crank out ...more  
69
Post by subaru1ion Mar 19, 2024 10:46am

Get it yet? NIH funding LABS clinical trial via Libby study

at USC?  No? Don't get it?  The clinical trial is for LABS pharmaceutical compounds and the NIH is funding that study because common sense, you should know, you want to prove out the ...more  
49
Post by subaru1ion Mar 19, 2024 10:43am

LABS is also a "clinical stage" pharma company. "over 20

strong clinical trials, may in late stage". How MUCH is that worth?   It's worth more than $2.4 billon even if LABS only has a 30% success rate on those 20+ clinical trials.   ...more  
121
Discussion
Comment by subaru1on Mar 19, 2024 10:41am

RE:Ever hear of FUSN? They just got taken out for $2.4B

Fusn went from $13,00 to $21,00 so Labs would go from $0,07 to $0,13 very far from $10,00 that u1i expect.
30
Discussion
Post by subaru1ion Mar 19, 2024 10:39am

LABS is involved with McMaster in the field of

antimicrobial resistance and development of new classes of antibiotics, recall cannabinoids tackling very diificult MRSA.   We'll be getting our reward very shortly as well. Gerry ...more  
79
Post by subaru1ion Mar 19, 2024 10:36am

Ever hear of FUSN? They just got taken out for $2.4B

The key here is their conjugate targeting technology or the 'heat seeking missle' to deliver a payload.  Pfizer already did that with Seagen and LABS will be providing pharmaceutical ...more  
97
Discussion
Comment by subaru1on Mar 19, 2024 10:30am

RE:Frustrating that Avicanna's share price has almost

Poor marketing is certainly one of the raison, or they don't have anything to share with us.
26
Discussion
Comment by subaru1ion Mar 19, 2024 10:25am

RE:Curaleaf jockeying to capitalize on a European position

It tells me something different, the move by Curaleaf....that LABS is 'hands off', we have a legal partner already otherwise LABS would have been a much better purchase by Curaleaf.  ...more  
42
Discussion
Post by mdjbrownon Mar 19, 2024 9:57am

Curaleaf jockeying to capitalize on a European position

Looks like the strategy is if you dont have GMP status, take out a company that does ....... Expecting big things with medicinal mj across the pond! https://www.stockwatch.com/News/Item/Z-C!CURA ...more  
62
Discussion
Prev ... 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities